RA
NVO

Ruggaard & Associates’s Novo Nordisk NVO Stock Holding History

Ruggaard & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,688
Closed -$260K – 126
2025
Q3 		$260K Buy
+4,688
New +$274K 0.1% 108

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ruggaard & Associates's NVO Position: Q4 2025 in Review

Ruggaard & Associates sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 4,688 shares — an estimated $260K sold.

Ruggaard & Associates first reported a position in NVO in Q3 2025 and held it in 1 quarter. The position peaked at $260K in Q3 2025. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Ruggaard & Associates reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Ruggaard & Associates sold 4,688 Novo Nordisk shares in Q4 2025, an estimated $260K.
  • Ruggaard & Associates first reported a position in Novo Nordisk in Q3 2025 and held it in 1 quarter.
  • Ruggaard & Associates's Novo Nordisk position peaked at $260K in Q3 2025.
  • 1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Ruggaard & Associates's 13F filing for Q4 2025, filed 20 Feb 2026.